Roche’s Polivy Combo Regime Under FDA Review For Type Of Blood Cancer
Roche Holdings AG (OTC:RHHBY) announced that the FDA accepted its supplemental marketing application for Polivy. Polivy is being developed by Roche…
Premier’s Q4 Sales, Profits Fall On Normalization Of COVID-19-Driven Demand
Premier Inc (NASDAQ:PINC) has reported Q4 FY22 revenue of $340.7 million, down 29% Y/Y, exceeding the consensus of $333.43 million. Supply…
NexImmune Pauses Developing Multiple Myeloma Hopeful, Citing Competition
NexImmune Inc (NASDAQ: NEXI) cited the competitive environment in the blood cancer space as the reason for
Sight Sciences Posts Long-Term Safety, Effectiveness Data For Glaucoma Surgical System
Sight Sciences Inc (NASDAQ: SGHT) announced 36-month post-surgery follow-up results of the OMNI Surgical System. The data demonstrates that the OMNI Surgical…
Merck Bets $250M On Next-Gen Approach To mRNA For Infectious Diseases, Cancer
Merck Co & Inc (NYSE:MRK) and Orna Therapeutics announced a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics…
Rapid Test For Monkeypox? NY-Based Chembio Diagnostics Thinks They Can Pull It Off
Chembio Diagnostics Inc (NASDAQ: CEMI) is
Amid Dwindling Quarterly Sales, Sema4 Announces More Layoffs
Sema4 Holdings Corp (NASDAQ:SMFR) reported Q2 revenues of $36.2 million compared to $47.0 million a year ago. Testing volumes on a…
T2 Biosystems Q2 Sales Below Expectations, Sticks To Annual Guidance
T2 Biosystems Inc’s (NASDAQ:TTOO) Q2 revenue reached $5.9 million, including product revenue of $2.6 million, representing decreases of 12% Y/Y…
Gritstone’s Cancer Drug Shows Strong Tumor-Specific Responses In Various Settings
Gritstone bio Inc (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy…
After Surprise Overall Survival Data In Metastatic Breast Cancer, Gilead Takes Complete Rights To Trodelvy
Everest Medicines will transfer all development and commercialization rights of Trodelvy (sacituzumab govitecan) to Gilead Sciences Inc (NASDAQ:GILD) in Greater China, South…